Phase 0 10 trials
Phase 0
NCT05432518 Jun 2023 → Jul 2027 expected adult glioblastoma AHS Cancer Control Alberta
Recruiting
No outcome recorded
Phase 0
NCT05238831 Jan 2023 → May 2026 female breast carcinoma , ovarian carcinoma , pancreatic ductal adenocarcinoma , pancreatic large cell neuroendocrine carcinoma +2 OHSU Knight Cancer Institute
Withdrawn
No outcome recorded
Phase 0
NCT05320757 Apr 2022 → May 2025 endometrial cancer The University of Hong Kong
Completed
No outcome recorded
Phase 0
NCT04614909 Jan 2021 → Jul 2023 adult glioblastoma Nader Sanai
Completed
No outcome recorded
Phase 0
NCT04005690 Aug 2019 → Jun 2026 overdue pancreatic ductal adenocarcinoma OHSU Knight Cancer Institute
Recruiting
No outcome recorded
Phase 0
NCT04041128 Jul 2019 → Jun 2021 breast cancer , ovarian cancer University of Texas Southwestern Medical Center
Completed
No outcome recorded
Phase 0
NCT03943173 Jun 2019 → Jun 2027 expected BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , fallopian tube serous adenocarcinoma , ovarian serous adenocarcinoma +1 M.D. Anderson Cancer Center
Active not recruiting
No outcome recorded
Phase 0
NCT03251872 Oct 2018 → Dec 2019 pulmonary arterial hypertension Laval University
Terminated
No outcome recorded
Phase 0
NCT03378297 May 2018 → Jan 2023 ovarian cancer Haukeland University Hospital
Completed
No outcome recorded
Phase 0
NCT02855697 May 2017 → Dec 2021 ovarian cancer The Christie NHS Foundation Trust
Completed
No outcome recorded
Phase 1 96 trials
Phase 1
NCT07382544 Feb 2026 → Jan 2030 expected cancer of unknown primary site M.D. Anderson Cancer Center
Recruiting
No outcome recorded
Phase 1
NCT06856499 Dec 2025 → Jul 2027 expected fallopian tube cancer , ovarian endometrial cancer , primary peritoneal carcinoma University of Colorado, Denver
Recruiting
No outcome recorded
Phase 1
NCT07090369 Nov 2025 → Dec 2028 expected castration-resistant prostate carcinoma Peter MacCallum Cancer Centre, Australia
Not yet recruiting
No outcome recorded
Phase 1
NCT07156253 Aug 2025 → Aug 2028 expected breast cancer , metastatic neoplasm , ovarian cancer Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Recruiting
No outcome recorded
Phase 1
NCT06976892 Aug 2025 → Dec 2029 expected malignant ovarian serous tumor Institute of Cancer Research, United Kingdom
Recruiting
No outcome recorded
Phase 1
NCT06686745 Dec 2024 → Jun 2027 expected cancer Jiangsu Simcere Pharmaceutical Co., Ltd.
Recruiting
No outcome recorded
Phase 1
NCT06560632 Sep 2024 → Oct 2025 neoplasm Repare Therapeutics
Terminated
No outcome recorded
Phase 1
NCT06545942 Aug 2024 → May 2027 expected breast cancer , metastatic neoplasm , ovarian cancer , pancreatic neoplasm +1 MOMA Therapeutics
Active not recruiting
No outcome recorded
Phase 1
NCT05900895 Jul 2024 → Dec 2027 expected breast cancer Mary D Chamberlin
Recruiting
No outcome recorded
Phase 1
NCT05932862 Apr 2024 → Jan 2029 expected neoplasm Exelixis
Recruiting
No outcome recorded
Phase 1
NCT06331559 Mar 2024 → Sep 2025 cancer Jiangsu Simcere Pharmaceutical Co., Ltd.
Terminated
No outcome recorded
Phase 1
NCT05807126 Mar 2024 → Dec 2026 castration-resistant prostate carcinoma , female breast carcinoma National Cancer Institute (NCI)
Withdrawn
No outcome recorded
Phase 1
NCT06177171 Feb 2024 → Jan 2028 expected ATM-related cancer predisposition , BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , CHEK2-related cancer predisposition +1 Varun Monga, MBBS
Recruiting
No outcome recorded
Phase 1
NCT06130254 Jan → Jun 2024 non-small cell lung carcinoma M.D. Anderson Cancer Center
Terminated
No outcome recorded
Phase 1
NCT05411094 May 2023 → Aug 2026 overdue digestive system carcinoma National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT05774886 May → Sep 2023 female breast carcinoma , triple-negative breast carcinoma Dana-Farber Cancer Institute
Withdrawn
No outcome recorded
Phase 1
NCT05358639 Nov 2022 → Mar 2025 overdue ovarian serous adenocarcinoma , triple-negative breast carcinoma Sunnybrook Health Sciences Centre
Active not recruiting
No outcome recorded
Phase 1
NCT05238922 Jul 2022 → Jul 2027 expected cancer Incyte Corporation
Recruiting
No outcome recorded
Phase 1
NCT05870423 Jun 2022 → Jan 2027 expected neuroendocrine neoplasm Erasmus Medical Center
Recruiting
No outcome recorded
Phase 1
NCT05252390 Mar 2022 → Jul 2024 malignant pancreatic neoplasm , ovarian carcinoma , prostate carcinoma , triple-negative breast carcinoma Nuvation Bio Inc.
Terminated
No outcome recorded
Phase 1
NCT04633239 Jul 2021 → Nov 2026 expected ovarian serous adenocarcinoma National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 1
NCT04585958 May 2021 → Dec 2026 expected metastatic malignant neoplasm , serous adenocarcinoma National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 1
NCT04550104 Mar 2021 → Mar 2026 overdue non-small cell lung carcinoma University of Leeds
Recruiting
No outcome recorded
Phase 1
NCT03685331 Oct 2020 → Aug 2025 BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , breast cancer Abramson Cancer Center at Penn Medicine
Completed
No outcome recorded
Phase 1
NCT03924245 Oct 2020 → Feb 2022 fallopian tube carcinosarcoma , fallopian tube clear cell adenocarcinoma , fallopian tube endometrioid adenocarcinoma , fallopian tube serous adenocarcinoma +5 Vanderbilt-Ingram Cancer Center
Terminated
No outcome recorded
Phase 1
NCT04197713 Jun 2020 → Feb 2023 overdue metastatic malignant neoplasm National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT04399876 Jun 2020 → Aug 2027 expected prostate cancer Brigham and Women's Hospital
Enrolling by invitation
No outcome recorded
Phase 1
NCT04375267 Apr 2020 → Jun 2024 mesothelioma , neuroendocrine neoplasm , thymoma Vastra Gotaland Region
Completed
No outcome recorded
Phase 1
NCT03878524 Apr → Dec 2020 acute myeloid leukemia , atypical chronic myeloid leukemia, BCR-ABL1 negative , blast phase chronic myelogenous leukemia, BCR-ABL1 positive , castration-resistant prostate carcinoma +14 OHSU Knight Cancer Institute
Terminated
No outcome recorded
Phase 1
NCT04236414 Jan 2020 → Feb 2025 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT03842228 Nov 2019 → Jul 2024 overdue metastatic malignant neoplasm National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT03259503 Sep 2019 → Nov 2025 Hodgkins lymphoma , T-cell non-Hodgkin lymphoma , diffuse large B-cell lymphoma M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1
NCT03874884 Jul 2019 → May 2025 overdue prostate carcinoma Peter MacCallum Cancer Centre, Australia
Active not recruiting
No outcome recorded
Phase 1
NCT03742245 Jun 2019 → Dec 2025 overdue breast carcinoma The Methodist Hospital Research Institute
Active not recruiting
No outcome recorded
Phase 1
NCT03923270 Jun 2019 → Jun 2023 overdue small cell lung carcinoma H. Lee Moffitt Cancer Center and Research Institute
Active not recruiting
No outcome recorded
Phase 1
NCT03955640 May 2019 → Aug 2021 breast carcinoma , malignant neoplasm of chest wall Thomas Jefferson University
Terminated
No outcome recorded
Phase 1
NCT03772561 Dec 2018 → Dec 2026 expected cancer National University Hospital, Singapore
Recruiting
No outcome recorded
Phase 1
NCT03641755 Oct 2018 → Apr 2022 overdue breast cancer Dana-Farber Cancer Institute
Active not recruiting
No outcome recorded
Phase 1
NCT03532880 Jul 2018 → Feb 2025 small cell lung carcinoma Memorial Sloan Kettering Cancer Center
Completed
No outcome recorded
Phase 1
NCT03553108 May 2018 → Mar 2019 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT03544125 May → Aug 2018 female breast carcinoma , triple-negative breast carcinoma OHSU Knight Cancer Institute
Completed
No outcome recorded
Phase 1
NCT02686008 Jan 2018 → Jan 2019 head and neck squamous cell carcinoma Yale University
Withdrawn
No outcome recorded
Phase 1
NCT03022409 Sep 2017 → Jan 2021 head and neck squamous cell carcinoma AstraZeneca
Completed
No outcome recorded
Phase 1
NCT03162627 Aug 2017 → Aug 2026 overdue breast cancer , digestive system cancer , female reproductive organ cancer , male reproductive organ cancer +1 M.D. Anderson Cancer Center
Active not recruiting
No outcome recorded
Phase 1
NCT03109080 Jul 2017 → Feb 2020 female breast carcinoma , triple-negative breast carcinoma Institut Curie
Completed
No outcome recorded
Phase 1
NCT03205176 Jun 2017 → Mar 2021 breast cancer , lymphoma , malignant pancreatic neoplasm , ovarian cancer +1 AstraZeneca
Completed
No outcome recorded
Phase 1
NCT02898207 May 2017 → Jul 2020 fallopian tube serous adenocarcinoma , high grade malignant neoplasm , metastatic malignant neoplasm , ovarian serous adenocarcinoma +2 National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1
NCT03057145 Mar 2017 → Feb 2020 cancer Geoffrey Shapiro, MD, PhD
Completed
No outcome recorded
Phase 1
NCT02546661 Dec 2016 → Mar 2020 overdue infiltrating bladder urothelial carcinoma AstraZeneca
Active not recruiting
No outcome recorded
Phase 1
NCT02324998 Dec 2016 → May 2019 prostate cancer Cambridge University Hospitals NHS Foundation Trust
Completed
No outcome recorded
Phase 1
NCT02485990 Jan 2016 → Mar 2020 primary peritoneal carcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Terminated
No outcome recorded
Phase 1
NCT02787642 Jan 2016 → Oct 2021 soft tissue sarcoma Institut Bergonié
Completed
No outcome recorded
Phase 1
NCT02561832 Nov 2015 → Sep 2016 breast cancer AstraZeneca
Terminated
No outcome recorded
Phase 1
NCT02308072 Sep 2015 → Jun 2020 head and neck cancer University College, London
Completed
No outcome recorded
Phase 1
NCT02511795 Aug 2015 → Apr 2019 refractory malignant neoplasm , small cell lung carcinoma AstraZeneca
Completed
No outcome recorded
Phase 1
NCT02430311 Jun 2015 → Jul 2016 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT02418624 May 2015 → Jan 2019 breast cancer , ovarian cancer The Netherlands Cancer Institute
Completed
No outcome recorded
Phase 1
NCT02208375 Nov 2014 → Jun 2028 expected BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , endometrium adenocarcinoma , fallopian tube carcinoma +4 M.D. Anderson Cancer Center
Active not recruiting
No outcome recorded
Phase 1
NCT02264678 Oct 2014 → Mar 2025 overdue —
AstraZeneca
Active not recruiting
No outcome recorded
Phase 1
NCT02229656 Sep 2014 → Jan 2020 head and neck neoplasm , larynx cancer , squamous cell carcinoma The Netherlands Cancer Institute
Unknown
No outcome recorded
Phase 1
NCT02093351 Sep 2014 → Apr 2015 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT02398058 Jul 2014 → Dec 2019 bone neoplasm , soft tissue sarcoma Italian Sarcoma Group
Completed
No outcome recorded
Phase 1
NCT02121990 Apr 2014 → Aug 2020 fallopian tube cancer , ovarian cancer , primary peritoneal carcinoma Memorial Sloan Kettering Cancer Center
Completed
No outcome recorded
Phase 1
NCT02338622 Mar 2014 → Mar 2016 cancer of unknown primary site Royal Marsden NHS Foundation Trust
Completed
No outcome recorded
Phase 1
NCT01894243 Mar 2014 → Nov 2016 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT01929603 Dec 2013 → May 2014 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT01894256 Nov 2013 → Mar 2015 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT02227082 Oct 2013 → Sep 2019 inflammatory breast carcinoma , triple-negative breast carcinoma The Netherlands Cancer Institute
Completed
No outcome recorded
Phase 1
NCT01900028 Oct 2013 → Apr 2014 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT01921140 Sep 2013 → Apr 2014 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT01851265 Jul → Oct 2013 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT01858168 Jul 2013 → Nov 2024 Ewing sarcoma , rhabdomyosarcoma Massachusetts General Hospital
Completed
No outcome recorded
Phase 1
NCT01460888 Jul 2013 → Jul 2015 carcinoma of esophagus The Christie NHS Foundation Trust
Unknown
No outcome recorded
Phase 1
NCT01813474 Mar 2013 → Aug 2016 high grade malignant neoplasm AstraZeneca
Completed
No outcome recorded
Phase 1
NCT01758731 Oct 2012 → Dec 2016 head and neck squamous cell carcinoma University of Colorado, Denver
Completed
No outcome recorded
Phase 1
NCT01623349 Sep 2012 → May 2019 breast cancer , ovarian cancer Dana-Farber Cancer Institute
Completed
No outcome recorded
Phase 1
NCT01562210 Apr 2012 → May 2019 non-small cell lung carcinoma The Netherlands Cancer Institute
Completed
No outcome recorded
Phase 1
NCT01390571 Jul 2011 → Jun 2017 central nervous system neoplasm Cancer Research UK
Completed
No outcome recorded
Phase 1
NCT01237067 Feb 2011 → Nov 2014 breast cancer , endometrial cancer , fallopian tube cancer , ovarian cancer +1 National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1
NCT01296763 Jan 2011 → Jan 2014 malignant pancreatic neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Completed
No outcome recorded
Phase 1
NCT00819221 Jan 2009 → Nov 2011 cancer AstraZeneca
Terminated
No outcome recorded
Phase 1
NCT00782574 Nov 2008 → Feb 2012 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT00777582 Oct 2008 → Feb 2009 overdue cancer AstraZeneca
Active not recruiting
No outcome recorded
Phase 1
NCT00707707 Sep 2008 → Nov 2009 triple-negative breast carcinoma AstraZeneca
Completed
No outcome recorded
Phase 1
NCT00710268 Jun 2008 → Mar 2009 metastatic neoplasm AstraZeneca
Completed
No outcome recorded
Phase 1
NCT01445418 May 2008 → Sep 2014 breast cancer , ovarian cancer National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1
NCT00678132 Apr 2008 → Nov 2010 neoplasm National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1
NCT00633269 Apr → Oct 2008 metastatic neoplasm AstraZeneca
Completed
No outcome recorded
Phase 1
NCT00535353 Jan 2008 → Sep 2012 colorectal cancer NCIC Clinical Trials Group
Completed
No outcome recorded
Phase 1
NCT00572364 Nov 2007 → Mar 2009 high grade malignant neoplasm AstraZeneca
Completed
No outcome recorded
Phase 1
NCT00515866 Aug 2007 → Oct 2011 pancreatic neoplasm AstraZeneca
Completed
No outcome recorded
Phase 1
NCT00516438 Jul 2007 → Mar 2009 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT00516724 Jun 2007 → Jan 2013 ovarian cancer , triple-negative breast carcinoma AstraZeneca
Completed
No outcome recorded
Phase 1
NCT00516802 Jan 2007 → Jan 2009 melanoma AstraZeneca
Completed
No outcome recorded
Phase 1
NCT00516373 Jul 2005 → Dec 2008 BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , ovarian cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT01491139 — squamous cell carcinoma University College, London
Withdrawn
No outcome recorded
Show 86 more trials Phase 1/2 37 trials
Phase 1/2
NCT07453394 Apr 2026 → Apr 2027 expected endometrial cancer , gastric cancer , non-small cell lung carcinoma , ovarian cancer Qilu Pharmaceutical Co., Ltd.
Not yet recruiting
No outcome recorded
Phase 1/2
NCT07460180 May 2025 → May 2027 expected epithelial neoplasm , fallopian tube cancer , ovarian cancer The Netherlands Cancer Institute
Recruiting
No outcome recorded
Phase 1/2
NCT06607692 Sep 2024 → Jul 2029 expected adrenal carcinoma , diffuse intrinsic pontine glioma , ependymoma , esthesioneuroblastoma +10 HM Hospitales
Recruiting
No outcome recorded
Phase 1/2
NCT06525298 Sep 2024 → Sep 2027 expected neoplasm Eisbach Bio GmbH
Recruiting
No outcome recorded
Phase 1/2
NCT06353386 May 2024 → Jan 2029 expected castration-resistant prostate carcinoma Merck Sharp & Dohme LLC
Recruiting
No outcome recorded
Phase 1/2
NCT06217757 Apr 2024 → Oct 2027 expected small cell lung carcinoma Sichuan University
Recruiting
No outcome recorded
Phase 1/2
NCT06298084 Mar 2024 → Sep 2027 expected HER2 positive breast carcinoma Gustave Roussy, Cancer Campus, Grand Paris
Recruiting
No outcome recorded
Phase 1/2
NCT06065059 Dec 2023 → May 2024 BRCA1-related cancer predisposition , hereditary breast carcinoma , malignant pancreatic neoplasm , ovarian carcinoma +1 Tango Therapeutics, Inc.
Terminated
No outcome recorded
Phase 1/2
NCT05975944 Sep 2023 small cell lung carcinoma Tianjin Medical University Cancer Institute and Hospital
Unknown
No outcome recorded
Phase 1/2
NCT05898399 Jun 2023 → Jun 2028 expected metastatic neoplasm , neoplasm Artios Pharma Ltd
Recruiting
No outcome recorded
Phase 1/2
NCT05933265 Jun 2023 → Jul 2026 overdue glioblastoma , metastatic neoplasm , non-small cell lung carcinoma , pancreatic adenocarcinoma +1 Lantern Pharma Inc.
Active not recruiting
No outcome recorded
Phase 1/2
NCT05700669 Feb → Oct 2023 breast cancer , malignant epithelial tumor of ovary , prostate carcinoma Valerio Therapeutics
Completed
No outcome recorded
Phase 1/2
NCT04086485 Oct 2022 → Jul 2027 expected digestive system neuroendocrine neoplasm National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 1/2
NCT05405309 Sep 2022 → Oct 2023 chronic lymphocytic leukemia/small lymphocytic lymphoma University of Utah
Terminated
No outcome recorded
Phase 1/2
NCT04711824 Mar 2022 → Jul 2026 overdue breast cancer , metastatic malignant neoplasm in the brain Colette Shen
Active not recruiting
No outcome recorded
Phase 1/2
NCT04592211 Oct 2021 → Dec 2025 overdue gastric cancer Yonsei University
Recruiting
No outcome recorded
Phase 1/2
NCT04972110 Jul 2021 → Nov 2024 —
Repare Therapeutics
Terminated
No outcome recorded
Phase 1/2
NCT04728230 Jan 2021 → Dec 2027 expected small cell lung carcinoma M.D. Anderson Cancer Center
Active not recruiting
No outcome recorded
Phase 1/2
NCT04410887 Dec 2020 → Dec 2021 gastric cancer Ruijin Hospital
Unknown
No outcome recorded
Phase 1/2
NCT03782818 Nov 2019 → Oct 2024 pulmonary arterial hypertension Laval University
Terminated
No outcome recorded
Phase 1/2
NCT03317392 Feb 2019 → Mar 2025 overdue castration-resistant prostate carcinoma , prostate adenocarcinoma National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1/2
NCT03594396 Jun 2018 → Dec 2025 overdue breast neoplasm Seoul National University Hospital
Active not recruiting
No outcome recorded
Phase 1/2
NCT03008278 Feb 2018 → Jun 2023 carcinoma of esophagus , gastric carcinoma , gastroesophageal junction adenocarcinoma National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1/2
NCT03212742 Sep 2017 → Sep 2026 expected malignant glioma Centre Francois Baclesse
Active not recruiting
No outcome recorded
Phase 1/2
NCT03085147 Mar 2017 → Jul 2026 overdue oral cavity squamous cell carcinoma Memorial Sloan Kettering Cancer Center
Active not recruiting
No outcome recorded
Phase 1/2
NCT02861573 Nov 2016 → Oct 2027 expected castration-resistant prostate carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 1/2
NCT02755844 Sep 2016 → Nov 2018 endometrial cancer Hospices Civils de Lyon
Completed
No outcome recorded
Phase 1/2
NCT02813135 Aug 2016 → Feb 2031 expected childhood malignant neoplasm Gustave Roussy, Cancer Campus, Grand Paris
Recruiting
No outcome recorded
Phase 1/2
NCT02769962 May 2016 → Apr 2023 prostate cancer , small cell lung carcinoma , urothelial carcinoma National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1/2
NCT02734004 Mar 2016 → Sep 2021 overdue breast disorder , gastric cancer , ovarian disorder , small cell lung carcinoma AstraZeneca
Active not recruiting
No outcome recorded
Phase 1/2
NCT02571725 Feb 2016 → Dec 2020 overdue fallopian tube cancer , ovarian cancer , peritoneal neoplasm New Mexico Cancer Research Alliance
Active not recruiting
No outcome recorded
Phase 1/2
NCT02446704 Oct 2015 → Dec 2022 small cell lung carcinoma Zofia Piotrowska
Unknown
No outcome recorded
Phase 1/2
NCT02684318 Jul 2015 → Jul 2019 breast cancer , cancer of unknown primary site , endometrial cancer , ovarian cancer Poveda, Andrés, M.D.
Unknown
No outcome recorded
Phase 1/2
NCT02484404 Jun 2015 → Oct 2027 expected breast cancer , colorectal cancer National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1/2
NCT01650376 Aug 2012 → Dec 2018 ovarian carcinoma , uterine cancer Swedish Medical Center
Unknown
No outcome recorded
Phase 1/2
NCT01513174 Aug 2011 → Jul 2016 non-small cell lung carcinoma Spanish Lung Cancer Group
Completed
No outcome recorded
Phase 1/2
NCT01116648 Apr 2010 → Oct 2018 overdue fallopian tube carcinoma , ovarian endometrioid adenocarcinoma , ovarian serous surface papillary adenocarcinoma , primary peritoneal serous adenocarcinoma +1 National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Show 27 more trials Phase 2 212 trials
Phase 2
NCT05522491 Sep 2026 → Sep 2030 expected neoplasm Hebei Medical University Fourth Hospital
Not yet recruiting
No outcome recorded
Phase 2
NCT07647653 Jun 2026 → Feb 2031 expected ovarian cancer Shandong University
Not yet recruiting
No outcome recorded
Phase 2
NCT07667751 Jun 2026 → Dec 2027 expected ovarian cancer Bai-Rong Xia
Recruiting
No outcome recorded
Phase 2
NCT05128734 Apr 2026 → Apr 2028 expected triple-negative breast carcinoma AHS Cancer Control Alberta
Not yet recruiting
No outcome recorded
Phase 2
NCT07407452 Feb 2026 → Dec 2027 expected ovarian cancer Jiangsu Cancer Institute & Hospital
Not yet recruiting
No outcome recorded
Phase 2
NCT07113964 Aug 2025 → Mar 2027 expected Her2-receptor negative breast cancer The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting
No outcome recorded
Phase 2
NCT07024784 Jul 2025 → Jan 2028 expected fallopian tube cancer , primary peritoneal carcinoma AbbVie
Recruiting
No outcome recorded
Phase 2
NCT07005583 Jun 2025 → May 2027 expected triple-negative breast carcinoma Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting
No outcome recorded
Phase 2
NCT05093231 Feb 2025 → Jul 2027 expected pancreatic adenocarcinoma Cambridge University Hospitals NHS Foundation Trust
Recruiting
No outcome recorded
Phase 2
NCT06909825 Feb 2025 → May 2027 expected metastatic prostate carcinoma Fusion Pharmaceuticals Inc.
Active not recruiting
No outcome recorded
Show all 212 trials opens the full record — a long page Phase 2/3 5 trials
Phase 2/3
NCT07641855 Jun 2026 → Dec 2028 expected castration-resistant prostate carcinoma Sichuan Baili Pharmaceutical Co., Ltd.
Not yet recruiting
No outcome recorded
Phase 2/3
NCT05432791 Mar 2023 → Aug 2024 overdue leiomyosarcoma of the corpus uteri National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2/3
NCT05255653 Nov 2021 → Jan 2030 expected endometrial cancer Leiden University Medical Center
Recruiting
No outcome recorded
Phase 2/3
NCT02502266 May 2016 → Jun 2023 overdue fallopian tube clear cell adenocarcinoma , fallopian tube endometrioid adenocarcinoma , fallopian tube serous adenocarcinoma , fallopian tube transitional cell carcinoma +7 National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2/3
NCT03150576 May 2016 → Jun 2024 overdue breast cancer Cambridge University Hospitals NHS Foundation Trust
Recruiting
No outcome recorded
Phase 3 36 trials
Phase 3
NCT06580314 Mar 2025 → Dec 2034 expected fallopian tube endometrioid adenocarcinoma , fallopian tube serous adenocarcinoma , ovarian endometrioid adenocarcinoma , ovarian serous adenocarcinoma +1 NRG Oncology
Recruiting
No outcome recorded
Phase 3
NCT06746116 Dec 2024 → Nov 2028 expected endometrial cancer AstraZeneca
Active not recruiting
No outcome recorded
Phase 3
NCT06712472 Jun 2024 → Jun 2030 expected endometrial cancer Gustave Roussy, Cancer Campus, Grand Paris
Recruiting
No outcome recorded
Phase 3
NCT05255471 Jan 2022 → Jan 2028 expected ovarian cancer National Cancer Institute, Naples
Recruiting
No outcome recorded
Phase 3
NCT04729387 Jul 2021 → Apr 2023 ovarian cancer Novartis Pharmaceuticals
Terminated
No outcome recorded
Phase 3
NCT05171816 Jun 2021 → Jan 2024 overdue prostate carcinoma AstraZeneca
Active not recruiting
No outcome recorded
Phase 3
NCT04884360 May 2021 → Jul 2026 overdue ovarian carcinoma AstraZeneca
Active not recruiting
No outcome recorded
Phase 3
NCT04624204 Dec 2020 → Oct 2027 expected small cell lung carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 3
NCT04456699 Aug 2020 → Mar 2023 colorectal cancer Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 3
NCT04421963 Aug 2020 → Apr 2027 expected breast cancer , ovarian cancer AstraZeneca
Active not recruiting
No outcome recorded
Phase 3
NCT04380636 Jul 2020 → May 2027 expected non-small cell lung carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 3
NCT04269200 May 2020 → Jul 2024 overdue endometrial cancer AstraZeneca
Active not recruiting
No outcome recorded
Phase 3
NCT03784014 Oct 2019 → Dec 2023 soft tissue sarcoma French National Institute of Health and Medical Research
Completed
No outcome recorded
Phase 3
NCT03976323 Jun 2019 → Feb 2024 non-small cell lung carcinoma Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 3
NCT03976362 Jun 2019 → Sep 2023 non-small cell squamous lung carcinoma Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 3
NCT03834519 May 2019 → Mar 2022 prostate neoplasm Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 3
NCT03737643 Jan 2019 → Mar 2025 overdue ovarian carcinoma AstraZeneca
Active not recruiting
No outcome recorded
Phase 3
NCT03740165 Dec 2018 → Aug 2024 fallopian tube cancer , ovarian cancer , peritoneal neoplasm Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 3
NCT03732820 Oct 2018 → Jul 2021 overdue prostate carcinoma AstraZeneca
Active not recruiting
No outcome recorded
Phase 3
NCT03486873 Aug 2018 → Aug 2043 expected cancer , hematopoietic and lymphoid cell neoplasm Merck Sharp & Dohme LLC
Recruiting
No outcome recorded
Phase 3
NCT03278717 Jun 2018 → Dec 2023 ovarian cancer University College, London
Unknown
No outcome recorded
Phase 3
NCT03534453 May 2018 → Jan 2025 —
AstraZeneca
Completed
No outcome recorded
Phase 3
NCT03402841 Jan 2018 → Oct 2020 —
AstraZeneca
Completed
No outcome recorded
Phase 3
NCT03286842 Jan 2018 → Oct 2021 Her2-receptor negative breast cancer AstraZeneca
Completed
No outcome recorded
Phase 3
NCT03106987 Jun 2017 → Feb 2021 malignant epithelial tumor of ovary AstraZeneca
Completed
No outcome recorded
Phase 3
NCT02987543 Feb 2017 → Jun 2019 prostate carcinoma AstraZeneca
Completed
No outcome recorded
Phase 3
NCT02392676 Jul 2016 → Jun 2019 —
AstraZeneca
Withdrawn
No outcome recorded
Phase 3
NCT02446600 Mar 2016 → Feb 2020 overdue fallopian tube clear cell adenocarcinoma , fallopian tube transitional cell carcinoma , ovarian clear cell adenocarcinoma , ovarian endometrioid adenocarcinoma +5 National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 3
NCT02477644 May 2015 → Mar 2019 ovarian cancer Arcagy Research
Completed
No outcome recorded
Phase 3
NCT02282020 Feb 2015 → Oct 2018 hereditary neoplastic syndrome AstraZeneca
Completed
No outcome recorded
Phase 3
NCT02184195 Dec 2014 → Jan 2019 hereditary breast ovarian cancer syndrome , pancreatic adenocarcinoma AstraZeneca
Completed
No outcome recorded
Phase 3
NCT02032823 Apr 2014 → Mar 2020 overdue breast cancer AstraZeneca
Active not recruiting
No outcome recorded
Phase 3
NCT02000622 Mar 2014 → Dec 2016 BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , breast carcinoma AstraZeneca
Completed
No outcome recorded
Phase 3
NCT01874353 Sep 2013 → Sep 2016 overdue hereditary neoplastic syndrome AstraZeneca
Active not recruiting
No outcome recorded
Phase 3
NCT01924533 Sep 2013 → Apr 2016 gastric cancer AstraZeneca
Completed
No outcome recorded
Phase 3
NCT01844986 Aug 2013 → May 2018 overdue hereditary breast ovarian cancer syndrome , ovarian cancer AstraZeneca
Active not recruiting
No outcome recorded
Show 26 more trials Phase 4 6 trials
Phase 4
NCT07695259 May 2026 → Dec 2027 expected HER2 positive breast carcinoma Wen-Ming Cao
Recruiting
No outcome recorded
Phase 4
NCT06121401 Sep 2023 → Mar 2027 expected malignant epithelial tumor of ovary Mario Negri Institute for Pharmacological Research
Active not recruiting
No outcome recorded
Phase 4
NCT05457257 Jul 2022 → Oct 2024 overdue castration-resistant prostate carcinoma AstraZeneca
Active not recruiting
No outcome recorded
Phase 4
NCT05078671 Dec 2021 → Dec 2025 cancer Radboud University Medical Center
Unknown
No outcome recorded
Phase 4
NCT04330040 May 2020 → Sep 2022 breast cancer , ovarian cancer AstraZeneca
Completed
No outcome recorded
Phase 4
NCT02476968 Sep 2015 → Apr 2020 neoplastic disease or syndrome AstraZeneca
Completed
No outcome recorded
Phase not applicable 3 trials
— NCT07187674 Dec 2025 → Jun 2028 expected triple-negative breast carcinoma Harbin Medical University
Not yet recruiting
No outcome recorded
— NCT04801966 Sep 2021 → Dec 2022 cancer Peter MacCallum Cancer Centre, Australia
Terminated
No outcome recorded
— NCT02681237 Apr 2016 → Jan 2022 ovarian cancer University Health Network, Toronto
Completed
No outcome recorded
Phase not stated 1 trial
— NCT03063710 — hereditary site-specific ovarian cancer syndrome AstraZeneca
No longer available
No outcome recorded